Baidu
map

西达本胺治疗外周T细胞淋巴瘤中国专家共识(2016版) 共识发布

2016-05-20 肿瘤瞭望 转自《肿瘤瞭望》

编者按:5月13日下午,由中国临床肿瘤学会(CSCO)、中国抗淋巴瘤联盟(UCLI)、中华医学会血液学分会(CSH)白血病-淋巴瘤学组、中国抗癌协会血液肿瘤专业委员会、中国抗癌协会淋巴瘤专业委员会共同参与制定的《西达本胺治疗外周T细胞淋巴瘤中国共识(2016版)》于北京发布。发布会由中国抗淋巴瘤联盟主席马军教授和上海交通大学附属瑞金医院的沈志祥教授主持,中国医学科学院石远凯教授、北京大学肿瘤医院朱

编者按:5月13日下午,由中国临床肿瘤学会(CSCO)、中国抗淋巴瘤联盟(UCLI)、中华医学会血液学分会(CSH)白血病-淋巴瘤学组、中国抗癌协会血液肿瘤专业委员会、中国抗癌协会淋巴瘤专业委员会共同参与制定的《西达本胺治疗外周T细胞淋巴瘤中国共识(2016版)》于北京发布。发布会由中国抗淋巴瘤联盟主席马军教授和上海交通大学附属瑞金医院的沈志祥教授主持,中国医学科学院石远凯教授、北京大学肿瘤医院朱军教授等编写组专家分享了西达本胺注册临床(CHIPEL)研究数据、上市后应用数据分析,专家共识的主要内容、要点解读、并对西达本胺的临床研究进展进行全面解读。与会专家就如何使用好西达本胺结合自己的临床经验进行了深入的讨论。

西达本胺CHIPEL研究及上市后主动监测数据——石远凯教授

石远凯教授首先介绍了西达本胺治疗复发或难治性外周T细胞淋巴瘤(PTCL)的关键性II期临床试验(CHIPEL试验)。该试验是多中心、开放性试验,全国有15家医院的淋巴瘤和血液临床研究中心参与此项研究。给药方案是30mg每周口服2次。独立委员会评价疗效ORR达到28%,其中缓解率最高的是血管免疫母细胞T细胞淋巴瘤,ORR为50%。46%患者6周临床收益(CR+PR+SD),此部分患者中位OS达到55个月。对比国外目前现有针对复发/难治性外周T患者二线治疗方案(包括化疗、普拉曲沙、罗米地辛、贝利司他),西达本胺的总体中位OS为21.4个月,优于其它方案。2015年版的中国恶性淋巴瘤诊疗规范就已将西达本胺列入治疗外周T细胞淋巴瘤的二线方案。

西达本胺上市后,截止2016年2月收集的383例有完整记录的PTCL患者数据。上市后以单药治疗为主,占2/3,另有1/3为联合治疗。单药的客观缓解率达到39%,联合用药的客观缓解率明显提升,达到51%。进一步分析提示,对于中高危的患者,含西达本胺的联合治疗可提高疗效,但合并使用化疗方案时应该注意两者不良反应。

图1. CHIPEL研究总体疗效

西达本胺治疗外周T细胞淋巴瘤中国共识——朱军教授

北京大学肿瘤医院的朱军教授向与会专家详细解读了该共识的核心内容。

西达本胺在上市后临床应用中已确认其单药疗效,目前临床很多专家也在探索更优疗效的方案,有多项西达本胺联合用药治疗PTCL的临床研究正在进行中,基本覆盖了目前常见的一线及二线方案。共识中针对不同类型患者的单药或联合用药做了临床应用的建议(图2)。其中不能耐受常规化疗的PTCL患者,也包括不能耐受一线化疗的患者,可选择单药作为一线治疗。西达本胺治疗单药治疗最常见的不良反应包括中性粒细胞、血小板减少及贫血。

图2. 共识中治疗PTCL的临床应用建议

西达本胺全球临床开发&中国上市后临床试验进展——宁志强博士

深圳微芯生物科技有限责任公司的宁志强博士介绍了西达本胺的全球临床开发情况。西达本胺目前在中国的临床开发计划包括针对首类适应症的单药临床试验研究(PTCL、CTCL)及以实体瘤为适应症开展的联合用药试验研究(非小细胞肺癌、乳腺癌)。他介绍了一项日本已完成的针对非霍奇金氏淋巴瘤(NHL)的I期临床试验。入组11例病人, 1例达到完全缓解(CR),5例达到部分缓解(PR)。此外还简要介绍了正在日本、韩国及美国开展的多项研究计划,机制研究等。西达本胺抗肿瘤的作用机制,包括增强NK及CTL的细胞杀伤活性、促进肿瘤细胞的抗原暴露以及下调免疫抑制剂Foxp3、IDO等的表达。西达本胺与靶向药物及免疫治疗药物的联用也正在研究中。

到会专家结合临床试验数据和临床使用经验,展开了深入讨论。大家普遍认为,截止目前接受西达本胺治疗的PTCL患者多为既往多次治疗失败的晚期患者,相比于早期复发患者,此类晚期复发患者疗效差,不良反应发生率高,因此在今后临床实践中,建议尽量选择早期复发患者推荐使用单药或联合治疗,即“二线首选”;也可诱导缓解后用作维持治疗。西达本胺的总体不良反应的发生率明显低于化疗,因此可作为长期口服维持治疗。联合GDP或CHOP时需要酌情减量,减少安全性问题发生率。沈志祥教授同时表示希望在尽快推进临床试验的同时及时公布结果。应建议患者在一线治疗缓解后进行维持治疗,虽然目前还没有循证医学证据,但也值得探索,维持时间经验性暂定6-12个月,根据研究进展再予以调整。

沈教授和马军教授总结指出《西达本胺治疗PTCL的中国专家共识(2016版)》发布是我国外周T细胞淋巴瘤(PTCL)治疗史上的一个里程碑,为PTCL的治疗开启了新的篇章,为PTCL患者的治疗提出了更多的解决方案。希望通过规范临床实践的应用和多项探索性临床研究方案的推进,有更多临床数据分析和循证医学证据指导PTCL疗效的进一步提升,更多患者获益,共识也将再此基础上不断发展更新。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-05-22 Kiste

    跟异基因移植哪个好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1741356, encodeId=e8141e4135679, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 02 15:26:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138132, encodeId=809413813207, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:17:41 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702386, encodeId=58e51e023860e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Sat Dec 17 04:26:00 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844477, encodeId=be3d18444e7a2, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Sun Jul 31 08:26:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86796, encodeId=27b386e963b, content=跟异基因移植哪个好, beContent=null, objectType=article, channel=null, level=null, likeNumber=201, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aba81626422, createdName=Kiste, createdTime=Sun May 22 06:10:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312203, encodeId=ea831312203f1, content=<a href='/topic/show?id=029d42e9060' target=_blank style='color:#2F92EE;'>#外周T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42790, encryptionId=029d42e9060, topicName=外周T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372613, encodeId=dbf013e261366, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 22 04:26:00 CST 2016, time=2016-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86686, encodeId=8d0b86686c0, content=外周T细胞淋巴瘤(PTCL)治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Fri May 20 17:03:00 CST 2016, time=2016-05-20, status=1, ipAttribution=)]
    2016-05-20 jetleo

    外周T细胞淋巴瘤(PTCL)治疗

    0

相关资讯

中国原创抗癌新药面世 研发过程堪比“走钢丝”

这是一种筚路蓝缕的开拓,14年的奋斗只为研发原创新药;这是一种苦心孤诣的探索,所有努力只为唤得春回大地归,推动中国原创药产业的发展;这是一种质朴深沉的感情,百折不挠只为回报生他养他的一方土地。  他是鲁先平,深圳微芯生物科技有限责任公司总裁,温文尔雅、彬彬有礼的外表下,是一颗滚烫的心,执着于斯,虽九死而未悔。  中国抗癌原创新药 “百死一生”成功“破冰”  2015年1月,微芯生物在深圳召开新

招募患者:西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验

1.试验药物简介 西达本胺是全球首个获准上市的亚型选择性组蛋白去乙酰化酶口服抑制剂,也是中国首个授权美国等发达国家专利使用的原创新药,首个适应症为复发及难治性外周T细胞淋巴瘤。本试验的适应症是晚期乳腺癌。 2.试验目的 本试验分为两个部分,即开放期和双盲对照期。 开放期: (1)主要目的:观察和评价药代动力学(PK)特征、药效动力学(PD)特征;(2)次要目的:观察和评价初步疗效和安全性

招募患者:西达本胺联合紫杉醇和卡铂治疗晚期非小细胞肺癌的Ⅱ期临床试验

ng: 0px; max-width: 100%; box-sizing: border-box !important; word-wrap: break-word !important;">国家省(州)城市1中国医学科学院肿瘤医院石远凯中国北京北京2天津医科大学附属肿瘤医院李凯中国天津天津3河北医科大学第四医院丁翠敏中国河北石家庄4四川省肿瘤医院余萍中国四川成都5江苏省肿瘤医院冯继峰/史美琪中国

Baidu
map
Baidu
map
Baidu
map